Xilio Therapeutics, Inc. (XLO)
Nasdaq: XLO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2021
Who owns Xilio Therapeutics, Inc.
As filed with the SECHolders of 5% or more
8
Gilead Sciences, Inc. holds 19.9% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed Feb 12, 2026 says.
Directors and officers
13
report now, of 22 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.
Holders of 5% or moreshare of the class, as filed
Gilead Sciences, Inc.
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock, par value $0.0001 per share · 19.9% in Aug 14, 2025
BCLS II Equity Opportunities, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · 8.5% in Feb 17, 2026
Orbimed Advisors LLC
SCHEDULE 13G · filed May 15, 2026 · Common Stock, par value $0.0001 per share
Coastlands Capital LP
SCHEDULE 13G · filed Dec 11, 2025 · Common Stock, par value $0.0001 per share
Sirenia Capital Management LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, par value $0.0001 per share
StemPoint Capital LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common stock, par value $0.0001 per share · 8.4% in Feb 17, 2026
Abbvie Inc.
SCHEDULE 13G · filed Feb 18, 2025 · Common Stock, par value $0.0001 per share
Frazier Life Sciences Public Fund, L.P.
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, par value $0.0001 per share · 9.9% in Aug 14, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 9.9% in Nov 14, 2025
Rock Springs Capital Management LP
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
What XLO reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 1 country, from the list filed with the 10-K filed Apr 1, 2024.
Insider tradesForm 4
2sales
1purchases
2sales on a scheduled plan
2people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 42 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Shannon James Samuel | director | 0 | $0 | 0 | 1 | $0 |
| Frankenfield Christopher James | Chief Financial Officer | 1 | $0 | 1 | 0 | $0 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | 1 | $0 | 1 | 0 | $0 |